Formulary Update Effective 4/20/2020

Date: February 13, 2020 To: Health Plan of San Joaquin (HPSJ) Physicians, Providers, and Pharmacies From: Health Plan of San Joaquin Pharmacy and Therapeutics Committee Subject: Formulary Update Business: Medi-Cal Effective 04/20/2020, the Pharmacy and Therapeutics Committee has approved the following changes: Additions to the Formulary: Phentermine (Adipex-P) 15mg, 30mg, 37.5mg capsule: No restrictions. Nateglinide […]

Read more

Improving the Quality of Care: Risks Associated with Use of Gabapentin

Learning Objectives: Review the U.S. Food and Drug Administration (FDA) approved indications for gabapentinoids (gabapentin and pregabalin). Describe potential risks associated with combining gabapentin with opioids. Summarize best practices for responsible prescribing of gabapentin. Key Points: Recent restrictions on opioid prescribing have led clinicians to utilize alternative or complementary approaches to pain management, especially for […]

Read more

Formulary Update Effective February 24, 2020

Date: December 12, 2019 To: Health Plan of San Joaquin (HPSJ) Physicians, Providers, and Pharmacies From: Health Plan of San Joaquin Pharmacy and Therapeutics Committee Subject: Formulary Update Effective February 24, 2020 Business: Medi-Cal Effective 02/24/2020, the Pharmacy and Therapeutics Committee has approved the following changes: Additions to the Formulary: Tranexamic Acid (Lysteda) 650 mg […]

Read more

Alert: New Global Guidelines for the Treatment of Asthma

The World Health Organization (WHO) and the National Heart, Lung, and Blood Institute (NHLBI) established the Global Initiative for Asthma (GINA) in 1993 in order to increase awareness about asthma among health professionals, public health authorities, and the community, and to improve asthma prevention and management through a coordinated worldwide effort. The GINA Scientific Committee […]

Read more

2019 Immunization Updates: Flu, HepA, HPV, Measles, CA School Requirements

Each year, the California Medi-Cal Drug Use Review (DUR) program issues an annual summary of updates on immunization guidelines, products, and/or research in collaboration with the California Department of Public Health (CDPH) Immunization Branch. For reference, the recommended immunization schedules for 2019 in the United States can be accessed on the Centers for Disease Control […]

Read more

Formulary Update – September 18, 2019

Date: September 18, 2019 To: Health Plan of San Joaquin (HPSJ) Physicians, Providers, and Pharmacies From: Health Plan of San Joaquin Pharmacy and Therapeutics Committee Subject: Formulary Update – September 18, 2019 Business: Medi-Cal Managed Care Effective 12/02/2019, the Pharmacy and Therapeutics Committee has approved the following changes: Additions to the Formulary: Heparin sodium porcine/PF […]

Read more

Clinical Review Update: Concomitant Anticholinergic and Antipsychotic Use

Learning Objectives: Understand the role of anticholinergic medications in the prevention and treatment of antipsychotic-induced extrapyramidal symptoms (EPS). Describe factors that should be considered when deciding to initiate and/or continue the concomitant use of anticholinergic with antipsychotic medication therapy. Key Points: Anticholinergic medications, including benztropine and trihexyphenidyl, are often prescribed to prevent or treat antipsychotic-induced […]

Read more

Clinical Review Update: Morphine Equivalent Daily Dose

Learning Objectives: Describe morphine equivalent daily dose (MEDD) and how it is being used to indicate potential dose-related risk for prescription opioid overdose. Summarize best practices for prescribing opioids. Identify resources available that promote responsible opioid prescribing, including online and mobile applications for calculation of morphine milligram equivalency. Describe recent legislation in California related to […]

Read more

Drug Safety Communication: Sleep Behavior Risks with Select Sleep Aids

Eszopiclone, zaleplon, and zolpidem are sedative-hypnotic medications approved for the treatment of insomnia in adults who experience difficulty falling or staying asleep. On April 30, 2019, the U.S. Food and Drug Administration (FDA) announced they are requiring safety label changes for eszopiclone, zaleplon, and zolpidem because of the risk of complex sleep behaviors, including sleepwalking, […]

Read more

Formulary Update effective 8/19/2019

Date: June 12, 2019 To: Health Plan of San Joaquin (HPSJ) Practitioners, Providers and Facilities From: Health Plan of San Joaquin Pharmacy and Therapeutics Committee Subject: Formulary Update effective 8/19/2019 Business: Medi-Cal Effective 8/19/2019, the Pharmacy and Therapeutics Committee has approved the following changes:   Additions to the Formulary: Semaglutide (Ozempic) Pen Injector:  PA required.  […]

Read more

1 2 3 6
top
X